---
title: "Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283188608.md"
description: "Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News"
datetime: "2026-04-17T12:01:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283188608.md)
  - [en](https://longbridge.com/en/news/283188608.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283188608.md)
---

# Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News

### Related Stocks

- [ADAG.US](https://longbridge.com/en/quote/ADAG.US.md)

## Related News & Research

- [Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028](https://longbridge.com/en/news/281429543.md)
- [Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach | TLX Stock News](https://longbridge.com/en/news/284280065.md)
- [Taysha To Present Preclinical Data On TSHA-102 Gene Therapy In Treatment Of Rett Syndrome](https://longbridge.com/en/news/284398488.md)
- [Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD | SILO Stock News](https://longbridge.com/en/news/284580361.md)
- [12:14 ETImmune Cells Rewire Themselves to Keep Battling Tumors in Nutrient Poor Environments](https://longbridge.com/en/news/284611566.md)